*Based on ORR for TRODELVY and single-agent chemotherapy as shown in Table 3 of the Summary of Product Characteristics.¹

†Assessed by independent central review in the ITT population. The ORR results in the primary analysis population (ORR: 35% vs 5%; OR: 10.8; 95% CI, 5.6–21.0) were consistent with the ITT population.² The primary analysis population consisted of patients without present or prior history of brain metastases (n=468). The ITT population consisted of patients with or without brain metastases at baseline (N=529). ^{1 ‡}Assessed by independent central review in the ITT population.2 CR defined as disappearance of all target lesions. Any pathological lymph nodes (whether target or non-target) must have reduction in short axis to <10 mm.^{3 §}Assessed by independent central review in the ITT population.2 PR defined as at least a 30% decrease in the sum of diameters of target lesions, taking as reference the baseline sum diameters.^{3 II}Assessed by independent central review in the ITT population. Clinical benefit rate defined as a CR, a PR, or stable disease with a duration of at least 6 months.